BioSpace News Archive

Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that Executive Chairman Christopher Schreiber will attend the “Hemp Industry Daily Forum” on Tuesday, December 10, 2019 as part of MJBizCon Week at the Las Vegas Convention Center in Las Vegas, Nevada.

Canadians want access to the latest treatments for themselves, their families and their friends— especially for cancers, rare diseases and conditions with limited treatment options.

Bayer today announced the publication of an analysis of the PROTECT VIII extension study in which a subset of 33 patients with hemophilia A who received five years of prophylactic treatment with Jivi® (antihemophilic factor [recombinant] PEGylated-aucl) maintained a safety and efficacy profile that was consistent with a prior analysis of the same subset, as well as with an analysis of the pivotal Phase III PROTECT VIII main study

Chubb announced today leadership appointments for North America Commercial Insurance, the company’s $5.8 billion retail commercial property and casualty (P&C) insurance division that serves middle market and small businesses through 48 offices in the United States and Canada.

Harris Williams, a global investment bank specializing in M&A advisory services, announces that it advised Longs Pharmacy Solutions (Longs), a portfolio company of Tailwind Capital (Tailwind), on its sale to PharMedQuest, a portfolio company of Kinderhook Industries, LLC (Kinderhook).

Imbed Biosciences Inc. (Imbed), a privately-held biotech company emerging as a leader in the development of advanced therapies for burns, chronic ulcers, and surgical wounds, announced today the launch of its new corporate and product brand identities, redesigned logos, and websites.

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved AVSOLA™ (infliximab-axxq) for all approved indications of the reference product, Remicade® (infliximab):

Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a leading global producer of plasma-derived medicines, today concluded more than a year of encouraging results of its AMBAR (Alzheimer Management by Albumin Replacement) clinical trial with the presentation of new neuroimaging data that show the reduction in the progression of the disease in patients with mild-to-moderate Alzheimer’s disease

Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Compensation Committee of Cara’s Board of Directors has approved the grant of non-qualified stock options to purchase an aggregate of 47,500 shares of common stock,

ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced the completion of its previously announced underwritten public offering of 47,782,500 shares of common stock at a price to the public of $3.13 per share, for gross proceeds of approximately $149.6 million